DuPont (DD)
Materials · $17.8B market cap · SEC CIK 0001666700
fundamentals score out of 100
Next reports on Nov 4, 2026, with analysts expecting $1.93 in earnings per share.
The case for DD
- Earnings per share up 147.3%.
- Barely leveraged. Debt is 0.23× equity.
- Current assets cover the near-term bills 2.4 times over.
- Pays a modest 2.0% dividend.
The case against
- Very expensive at 324.1× earnings. Years of growth are already in the price.
- Revenue has shrunk 9.3% a year over five years.
- Return on equity of only 0%.
- Net margin of 2.8% leaves very little room for error.
- Free cash flow is only 1.3% of its market value, a thin cash return for the price.
What the score is made of
Each factor is half a curve over reported figures and half a rank among the other Materials companies (momentum is judged against fixed thresholds only), and the five are blended by weight. It describes the last filing and the current price. It is not a forecast.
| Valuewhat you pay for the earnings, sales, assets and cash | 24 |
|---|---|
| Growthhow fast revenue and earnings are moving, this year and over five | 27 |
| Profitabilityhow much of the revenue becomes profit, and how much of that is cash | 35 |
| Momentumhow the price has behaved lately | 57 |
| Stabilityhow violently it moves, what it owes and what it pays you | 67 |
- Each factor except momentum is half fixed thresholds, half rank among the 26 Materials companies.
Key numbers
| Price / earnings | 324.1× |
|---|---|
| Price / book | 1.33× |
| Price / sales | 2.7× |
| Revenue growth (YoY) | +5.6% |
| EPS growth (YoY) | +147.3% |
| Gross margin | 37% |
| Operating margin | 13% |
| Net margin | 3% |
| Return on equity | 0% |
| Debt / equity | 0.23× |
| Current ratio | 2.43 |
| Dividend yield | 2.01% |
| Beta | 1.06 |
| 52-week range | $92.49 – $157.98 |
| Position in that range | 60% of the way up |
| 3-month return | -9.3% |
| 1-year return | +32.4% |
Five years of financials, as filed
Pulled from DuPont's XBRL filings on SEC EDGAR. Italic rows are derived from the rows above.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $6.8B | $6.7B | $6.6B | $13.0B | $12.6B |
| Net income | $88.0M | $703M | $423M | $5.9B | $6.5B |
| Operating cash flow | $560M | $765M | $845M | $588M | $2.3B |
| Capital expenditure | $333M | $285M | $302M | $662M | $788M |
| Total assets | $21.6B | $36.6B | $38.6B | $41.4B | $45.7B |
| Total liabilities | $7.5B | $12.8B | $13.8B | $14.3B | $18.7B |
| Shareholder equity | $13.9B | $23.4B | $24.3B | $26.6B | $26.4B |
| Cash | $715M | $1.8B | $2.4B | $3.7B | $2.0B |
| Long-term debt | — | — | $7.9B | $8.1B | $10.6B |
| Free cash flow | $227M | $480M | $543M | -$74.0M | $1.5B |
| Net margin | 1.3% | 10.5% | 6.4% | 45.1% | 51.5% |
| Diluted shares | 419M | 419M | 450M | 499M | 544M |
Share count is down 23.0% over 4 years. Buybacks have been shrinking the pie.
What DuPont says it does
Throughout this Annual Report on Form 10-K, except as otherwise noted by the context, the terms "DuPont" or "Company" used herein mean DuPont de Nemours, Inc. and its consolidated subsidiaries. DuPont is a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. The Company is committed to helping customers advance their technology pipelines and provide solutions that address their unique challenges. From delivering clean water to enabling medical packaging solutions which enhance safety and performance, DuPont's innovations power the essential products and technologies people rely on every day. At December 31, 2025, the Company has subsidiaries in about 50 countries worldwide and manufacturing operations in about 20 countries. See Note 23 to the Consolidated Financial Statements for details on the location of the Company's sales and property. Transformational…
Risk factors DD lists in its 10-K
- Risks Relating to the Qnity Distribution, M&M Divestitures, N&B Transaction, the DWDP Distributions and the Aramids Divestiture
- DuPont could incur additional tax liabilities if certain internal transactions undertaken in connection with the completed divestiture of a majority of the Mobility & Materials business to Celanese and divestiture of the Delrin
- business to TJC (the "M&M Divestitures"), fail to qualify for their intended tax treatment
- The separation and combination of DuPont’s Nutrition & Biosciences business with IFF could result in a significant tax liability to DuPont
- DuPont is subject to continuing contingent tax-related liabilities of Dow and Corteva following the DWDP Distributions
- The timing and outcome of the Aramids Divestiture is subject to risk and uncertainties
- Risks Relating to DuPont’s Business and Results of Operations
- Enforcing the Company’s intellectual property rights, or defending against intellectual property claims asserted by others, could adversely affect the Company’s business, results of operations, financial condition and cash flows
- An impairment of goodwill or intangible assets could negatively impact the Company’s financial results
- Failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions could adversely impact the Company’s business, results of operations, financial condition and cash flows
- Failure to maintain a streamlined operating model and sustain operational improvements may reduce the Company’s profitability or adversely impact the Company’s business, results of operations, financial condition and cash flows
- The Company’s results are affected by its ability to foresee and respond to competitive conditions and customer preferences
- Failure to attract and retain talented people with the necessary knowledge and experience could adversely affect Company’s ability to compete and achieve its strategic goals
- Risks Relating to Capital Resources and Liquidity